Inhibition of insulin-regulated aminopeptidase confers neuroprotection in a conscious model of ischemic stroke

• Published in: Scientific reports 2023-11, Vol.13 (1), p.19722-19722, Article 19722
• Main Authors: Telianidis, Jonathon, Hunter, Andrew, Widdop, Robert, Kemp-Harper, Barbara, Pham, Vi, McCarthy, Claudia, Chai, Siew Yeen
• Format: Article
• Language: English
• Subjects: 631/378; 692/617; Aminopeptidase; Animal models; Astrocytes; CD11b antigen; Chemokines; Drug development; Drug therapy; Endothelin 1; Gene deletion; Gene expression; Humanities and Social Sciences; Hypertension; Inflammation; Inhibitors; Insulin; Interleukin 6; Ischemia; Molecular weight; Morbidity; multidisciplinary; Neurological diseases; Neuroprotection; Science; Science (multidisciplinary); Stroke; Ventricle; Ventricles (cerebral)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-46072-5

Stroke is a leading cause of mortality and morbidity with a paucity of effective pharmacological treatments. We have previously identified insulin-regulated aminopeptidase (IRAP) as a potential target for the development of a new class of drugs for the treatment of stroke, as global deletion of this gene in mice significantly protected against ischemic damage. In the current study, we demonstrate that small molecular weight IRAP inhibitors reduce infarct volume and improve neurological outcome in a hypertensive animal model of ischemic stroke. The effects of two structurally distinct IRAP inhibitors (HFI419 or SJM164) were investigated in a model of stroke where the middle cerebral artery was transiently occluded with endothelin-1 in the conscious spontaneously hypertensive rat. IRAP inhibitor was administered into the lateral ventricle at 2 or 6 h after stroke, with subsequent doses delivered at 24, 48 and 70 h post-stroke. Functional outcomes were assessed prior to drug treatment, and on day 1 and 3 post-stroke. Histological analyses and neuroinflammatory cytokine profiling were conducted at 72 and 24 h post-stroke respectively. IRAP inhibitor treatment following stroke significantly reduced infarct volume and improved neurological and motor deficits. These protective effects were maintained even when the therapeutic window was extended to 6 h. Examination of the cellular architecture at 72 h post-stroke demonstrated that IRAP expression was upregulated in CD11b positive cells and activated astrocytes. Furthermore, IRAP inhibitor treatment significantly increased gene expression for interleukin 6 and C–C motif chemokine ligand 2 in the ischemic core. This study provides proof-of-principle that selective inhibition of IRAP activity with two structurally distinct IRAP inhibitors reduces infarct volume and improves functional outcome even when the first dose is administered 6 h post-stroke. This is the first direct evidence that IRAP inhibitors are a class of drug with potential use in the treatment of ischemic stroke.